Open AccessIn Vivo Alemtuzumab Enables Haploidentical Human Leukocyte Antigen-Mismatched Hematopoietic Stem-Cell Transplantation Without Ex Vivo Graft Manipulation
Author(s) -
Yoshinobu Kanda,
Kumi Oshima,
Yuki AsanoMori,
Koji Kandabashi,
Masahiro Nakagawa,
Mamiko SakataYanagimoto,
Koji Izutsu,
Akira Hangaishi,
Shiho Tsujino,
Seishi Ogawa,
Toru Motokura,
Shigeru Chiba,
Hisamaru Hirai
Publication year - 2005
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/01.tp.0000158718.49286.14
Subject(s) - alemtuzumab , medicine , transplantation , cd52 , fludarabine , total body irradiation , hematopoietic stem cell transplantation , ex vivo , immunology , graft versus host disease , cumulative incidence , stem cell , gastroenterology , leukemia , surgery , in vivo , chemotherapy , biology , cyclophosphamide , genetics , microbiology and biotechnology
Alemtuzumab, a humanized monoclonal antibody directed against human CD52, has a strong lympholytic effect. This study evaluates the safety of unmanipulated peripheral blood stem-cell transplantation from two or three loci-mismatched related donors using alemtuzumab in vivo.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom